Arcus Biosciences Inc (NYSE:RCUS) Director Kathryn E. Falberg bought 20,000 shares of the stock in a transaction on Wednesday, June 12th. The stock was purchased at an average price of $8.20 per share, for a total transaction of $164,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of NYSE:RCUS traded down $0.26 during midday trading on Friday, reaching $8.28. 13,177 shares of the company traded hands, compared to its average volume of 139,363. Arcus Biosciences Inc has a 12 month low of $7.40 and a 12 month high of $17.18. The firm has a market cap of $369.20 million, a price-to-earnings ratio of -5.79 and a beta of 1.22.
Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.25 million. On average, sell-side analysts predict that Arcus Biosciences Inc will post -1.64 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in RCUS. Svennilson Peter bought a new stake in shares of Arcus Biosciences during the 4th quarter valued at $38,135,000. BlackRock Inc. grew its position in Arcus Biosciences by 295.5% during the fourth quarter. BlackRock Inc. now owns 1,721,894 shares of the company’s stock worth $18,545,000 after buying an additional 1,286,470 shares in the last quarter. Aisling Capital Management LP purchased a new position in Arcus Biosciences during the fourth quarter worth about $5,778,000. Hillhouse Capital Advisors Ltd. purchased a new position in Arcus Biosciences during the fourth quarter worth about $4,577,000. Finally, BVF Inc. IL grew its position in Arcus Biosciences by 16.5% during the first quarter. BVF Inc. IL now owns 2,810,223 shares of the company’s stock worth $35,100,000 after buying an additional 398,600 shares in the last quarter. Institutional investors own 46.58% of the company’s stock.
A number of analysts recently issued reports on the company. Citigroup decreased their price objective on Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a research note on Wednesday, June 5th. Zacks Investment Research lowered Arcus Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Svb Leerink reiterated an “outperform” rating on shares of Arcus Biosciences in a research note on Friday, May 3rd. Finally, BTIG Research assumed coverage on Arcus Biosciences in a research note on Monday, March 18th. They set a “buy” rating and a $20.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.50.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
See Also: How Short Selling Works
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.